Gossamer Bio's Seralutinib Fails Phase 3 PROSERA Trial Due to Stringent Statistical Threshold
Key Insights
Gossamer Bio's Phase 3 PROSERA (search) trial of seralutinib missed its primary endpoint with a p-value of 0.032, failing to meet the pre-specified alpha threshold of 0.025.
The company's stock lost more than 60% of its value following the trial failure announcement in February 2026.
Management had expressed optimism about positive results in May 2025 but did not disclose the heightened statistical threshold that was twice as stringent as conventional levels.
Gossamer Bio's Phase 3 PROSERA (search) trial of seralutinib has failed to meet its primary endpoint, resulting in a dramatic stock decline of more than 60% following the announcement in February 2026. The trial's failure was attributed to a stringent statistical threshold that was not adequately disclosed to investors during prior guidance communications.
Statistical Design Creates Technical Miss
The PROSERA (search) study's pre-specified statistical plan required significance at alpha = 0.025, a threshold twice as stringent as the conventional 0.05 level used in many pivotal trials. The actual p-value came in at 0.032, which would have cleared a standard 0.05 statistical bar but failed to meet the more rigorous 0.025 requirement built into the study design.
This statistical design choice proved critical to the trial's outcome, as the results fell into the narrow range between the two thresholds. Under conventional statistical criteria used in most pharmaceutical trials, seralutinib would have achieved statistical significance for its primary endpoint.
Management Guidance and Disclosure Concerns
In May 2025, CEO Faheem Hasnain provided forward-looking guidance during the Q1 2025 earnings call, stating that the company anticipated "announcing top-line results in February 2026." At that time, management expressed they were "more optimistic than ever about the likelihood of achieving positive results."
However, at the time of that statement on May 15, 2025, the company did not disclose to investors that the PROSERA (search) study required the heightened statistical threshold of alpha = 0.025. This omission meant that investors who relied on management's forward-looking statements had no way to assess the elevated risk of a technical miss due to the more stringent statistical requirements.
Market Impact and Investor Response
The gap between the optimistic guidance tone and the undisclosed statistical hurdle has drawn attention from securities firms. The forward guidance created specific expectations for results in February 2026, with management's positive statements setting investor expectations for a meaningful readout.
The dramatic stock decline of more than 60% reflects the market's reaction to both the trial failure and the revelation of the statistical design that contributed to the miss. Investors who purchased shares based on the forward-looking statements faced significant losses when the results were announced.